Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients
Kaitlin Rascon(University of Houston), Ekim Ekinci(Houston Methodist), Carmine De Angelis(Baylor College of Medicine), Meghana V. Trivedi(University of Houston), Goran Flajc(University of Houston), Xinli Liu(University of Houston)
Cited by 22
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168